title: Aripiprazole: in major depressive disorder.
abstract: Aripiprazole, an oral quinolinone, is the first atypical antipsychotic agent to be approved in the US as adjunctive treatment in adult patients with major depressive disorder (MDD). In two large, well-designed trials in patients with MDD who had an inadequate response to standard antidepressant therapy, 6 weeks' adjunctive therapy with aripiprazole 2-20 mg/day improved mean Montgomery Asberg Depression Rating Scale (MADRS) total scores (primary endpoint) to a significantly greater extent than adjunctive placebo treatment. Improvements in mean MADRS total score during the double-blind phase favoured adjunctive aripiprazole treatment from 1-2 weeks onward, with per-protocol subgroup analyses showing that mean changes were not affected by the specific standard antidepressant therapy used, age or sex of the patient or the mean MADRS total scores at the start of double-blind adjunctive therapy. In general, secondary endpoint scores, including those for the Sheehan Disability Scale, Clinical Global Impression (CGI) Improvement scale and CGI Severity of Illness scale, improved to a significantly greater extent with adjunctive aripiprazole than with adjunctive placebo treatment, with significantly higher response and remission rates in the aripiprazole groups. In these two pivotal trials, adjunctive aripiprazole 2-20 mg/day was generally well tolerated, with most treatment-emergent adverse events being of mild to moderate severity.
authors.affiliation: Wolters Kluwer Health | Adis, Auckland, New Zealand.
authors.forename: Juliane
authors.initials: J
authors.lastname: Weber
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Lyseng-Williamson
authors.forename: Lesley J
authors.initials: LJ
authors.lastname: Scott
mesh_terms: D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068180:Aripiprazole; D002986:Clinical Trials as Topic; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004185:Disability Evaluation; D004361:Drug Tolerance; D006801:Humans; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015363:Quinolones / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole
references.citation: J Clin Pharmacol. 2004 Feb;44(2):179-87
references.pmid: 14747427
references.citation: CNS Drugs. 2008;22(4):335-52
references.pmid: 18336061
references.citation: Eur J Pharmacol. 2002 Apr 26;441(3):137-40
references.pmid: 12063084
references.citation: Drugs. 2004;64(15):1715-36
references.pmid: 15257633
references.citation: Neuropsychopharmacology. 2002 Aug;27(2):248-59
references.pmid: 12093598
references.citation: J Clin Psychiatry. 2004;65 Suppl 18:47-56
references.pmid: 15600384
references.citation: J Psychiatr Pract. 2008 Jan;14(1):34-44
references.pmid: 18212601
references.citation: J Clin Psychiatry. 2005;66 Suppl 8:5-12
references.pmid: 16336031
references.citation: Psychiatr Clin North Am. 2007 Mar;30(1):13-29
references.pmid: 17362800
references.citation: CNS Drugs. 2007;21(11):911-36
references.pmid: 17927296
references.citation: J Pharmacol Exp Ther. 2002 Jul;302(1):381-9
references.pmid: 12065741
references.citation: Acta Psychiatr Scand. 2008 Apr;117(4):253-9
references.pmid: 18190674
references.citation: Int Clin Psychopharmacol. 2008 Mar;23(2):63-9
references.pmid: 18301120
references.citation: CNS Drugs. 2008;22(5):367-88
references.pmid: 18399707
references.citation: J Clin Psychiatry. 2007 Jun;68(6):843-53
references.pmid: 17592907
references.citation: J Clin Psychopharmacol. 2008 Apr;28(2):156-65
references.pmid: 18344725
references.citation: J Clin Psychiatry. 2006;67 Suppl 6:16-22
references.pmid: 16848672